```html

Tuberculosis (Pulmonary) – A Comprehensive Medical Guide

Overview

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis. When the bacteria primarily involve the lungs, the condition is called pulmonary tuberculosis. TB is transmitted through airborne droplets when a person with active pulmonary disease coughs, sneezes, speaks, or sings.
Globally, TB remains one of the top 10 causes of death and the leading cause from a single infectious agent (> 1.5 million deaths in 2022) <sup>WHO</sup>. In the United States, the Centers for Disease Control and Prevention (CDC) reported ≈ 8,200 new cases in 2022, a rate of 2.5 per 100,000 people <sup>CDC</sup>. TB can affect anyone, but the highest burden is among:

• People living in crowded or poorly ventilated settings (e.g., prisons, shelters)
• Individuals with weakened immune systems (HIV infection, diabetes, chronic kidney disease)
• Those with a history of prior TB exposure or infection
• People born in or who have traveled to countries where TB is endemic (e.g., India, China, South Africa)

While many infected individuals remain asymptomatic (latent TB infection), about 5‑10 % will develop active pulmonary disease during their lifetime if untreated.

Symptoms

Symptoms of active pulmonary TB develop slowly—often weeks to months after infection. They may be mild at first, making early detection challenging.

• Persistent cough – usually lasting > 3 weeks; may be dry or produce sputum.
• Hemoptysis – coughing up blood or blood‑streaked sputum.
• Fever – low‑grade, often worse in the evenings.
• Night sweats – drenching sweats that soak clothing and bedding.
• Unexplained weight loss – “consumption” – loss of appetite and fat stores.
• Fatigue & weakness – generalized tiredness that interferes with daily activities.
• Chest pain – may be pleuritic (sharp, worsens with breathing) if pleura is involved.
• Shortness of breath – especially when disease progresses to extensive lung involvement.
• Loss of appetite – can exacerbate weight loss.

Because these signs overlap with other respiratory illnesses, laboratory confirmation is essential before starting treatment.

Causes and Risk Factors

What Causes Pulmonary TB?

The disease is caused by inhalation of aerosolized droplets containing M. tuberculosis. The bacteria can survive in the environment for weeks under ordinary conditions. Once inhaled, they reach the alveoli, where they are engulfed by macrophages. In most healthy individuals, the immune response contains the infection, leading to a dormant (latent) state. If the immune system is compromised or the bacterial load is high, the organisms multiply, causing active disease.

Key Risk Factors

• Immunosuppression: HIV infection increases TB risk > 20‑fold. Other conditions such as cancer, organ transplantation, corticosteroid therapy, and biologic agents also elevate risk.
• Chronic diseases: Diabetes triples the risk; chronic kidney disease, silicosis, and severe malnutrition similarly predispose.
• Social determinants: Poverty, homelessness, substance abuse (alcohol, illicit drugs), and incarceration facilitate transmission.
• Age: Children < 5 years and adults > 65 years are more vulnerable to progression.
• Close contact: Living or working with someone who has active pulmonary TB.
• Geography: Origin from or travel to high‑incidence regions (≥ 100 cases per 100,000).

Diagnosis

Diagnosing pulmonary TB involves a combination of clinical assessment, radiographic imaging, and microbiologic testing.

1. Medical History & Physical Exam

Clinicians ask about cough duration, exposure history, risk factors, and systemic symptoms. Physical findings may include crackles, pleural rub, or lymphadenopathy.

2. Chest Radiography (X‑ray)

Typical findings:

• Upper‑lobe infiltrates or cavitary lesions
• Hilar or mediastinal lymph node enlargement
• Diffuse infiltrates in advanced disease

While not definitive, a CXR helps prioritize further testing.

3. Microbiologic Tests

• Sputum smear microscopy: Ziehl‑Neelsen or fluorescence staining for acid‑fast bacilli (AFB). Provides rapid (‑same‑day) results but lower sensitivity.
• Nucleic acid amplification tests (NAAT): Examples include GeneXpert MTB/RIF, which detects TB DNA and rifampin resistance within 2 hours. Recommended by WHO as an initial test.
• Culture: Gold standard; grows on solid (Lowenstein‑Jensen) or liquid (MGIT) media. Takes 2‑8 weeks but allows full drug‑susceptibility testing.
• Drug‑susceptibility testing (DST): Determines resistance to first‑line drugs (isoniazid, rifampin, ethambutol, pyrazinamide) and guides regimen selection.

4. Additional Tests (when needed)

• Interferon‑γ release assays (IGRA) or tuberculin skin test (TST) – used to detect latent infection, not active disease.
• HIV testing – recommended for all TB patients because co‑infection alters management.
• Blood work (CBC, liver function) – baseline before starting therapy.

Treatment Options

Effective treatment requires a combination of antibiotics taken for an extended period to eradicate both actively dividing and dormant bacilli and to prevent resistance.

1. First‑Line (Standard) Regimen

For drug‑susceptible TB, the WHO and CDC recommend a 6‑month regimen:

• Intensive phase (2 months): Isoniazid (INH) + Rifampin + Pyrazinamide + Ethambutol (HRZE).
• Continuation phase (4 months): Isoniazid + Rifampin (HR).

Directly observed therapy (DOT) is encouraged to ensure adherence.

2. Drug‑Resistant TB

• Multidrug‑resistant TB (MDR‑TB): Resistance to at least INH and rifampin. Treatment lasts 9‑20 months with second‑line drugs (fluoroquinolones, bedaquiline, linezolid, cycloserine, etc.).
• Extensively drug‑resistant TB (XDR‑TB): MDR‑TB plus resistance to any fluoroquinolone and at least one second‑line injectable. Requires individualized regimens, often > 20 months, and may involve newer agents (delamanid, pretomanid).

3. Adjunctive Therapies & Procedures

• Corticosteroids: Indicated for TB meningitis, pericarditis, or severe respiratory compromise (e.g., TB pleuritis with large effusion).
• Surgical resection: Rarely used for localized cavitary disease resistant to drugs or for complications such as bronchiectasis.

4. Lifestyle & Supportive Measures

• Take medications exactly as prescribed; never skip doses.
• Maintain a balanced diet rich in protein, vitamins A, D, and C to support immunity.
• Avoid alcohol and tobacco—both impair drug metabolism and lung healing.
• Stay hydrated; use a humidifier if cough is dry.
• Inform close contacts and arrange screening (often a single‑dose isoniazid preventive therapy is offered).

Living with Tuberculosis (pulmonary)

Managing TB goes beyond medication; it involves daily habits that promote recovery and protect others.

Medication Management

• Use a pill organizer or phone alarms to track doses.
• Keep a medication diary; note side effects and report them promptly.
• Attend all follow‑up appointments for sputum monitoring (usually at 2, 5, and 6 months).

Infection Control at Home

• Sleep in a well‑ventilated room; keep windows open when weather permits.
• Wear a surgical mask when coughing or sneezing; replace daily.
• Cover mouth and nose with a tissue or elbow; discard tissues immediately.
• Limit time spent in enclosed spaces with infants, elderly, or immunocompromised individuals until sputum cultures are negative.

Nutrition & Rest

• Aim for 2,200–2,500 kcal per day (more if weight loss > 10 %).
• Include lean proteins (legumes, poultry, fish), whole grains, and plenty of fruits/vegetables.
• Vitamin D supplementation (800–1,000 IU daily) may be beneficial, especially in those with deficiency.
• Prioritize 7‑9 hours of sleep; use a supportive pillow to ease coughing at night.

Psychosocial Support

• Join a TB support group—sharing experiences reduces isolation.
• Seek counseling if depression or anxiety develops; chronic illness can affect mental health.
• Utilize public health resources for transportation, medication vouchers, or food assistance.

Prevention

Preventing transmission and infection is possible with a combination of public‑health measures and personal behaviors.

• Vaccination: Bacille Calmette‑Guérin (BCG) vaccine provides modest protection against severe childhood TB; it is not routinely used in the U.S. but is standard in high‑burden countries.
• Screening of high‑risk groups: Annual TB testing for health‑care workers, people living with HIV, and recent immigrants from endemic areas.
• Latent TB treatment: Isoniazid for 6–9 months, rifampin for 4 months, or weekly rifapentine + isoniazid for 3 months reduces progression to active disease.
• Infection‑control practices in congregate settings: UV germicidal irradiation, negative‑pressure rooms, and respirator (N95) use for staff.
• Public education: Emphasize cough etiquette, early medical evaluation for persistent cough, and reducing stigma that delays care.

Complications

If untreated or inadequately treated, pulmonary TB can cause serious, sometimes irreversible damage.

• Cavitary lung disease: Permanent cavities may harbor bacteria and lead to chronic cough, hemoptysis, and secondary bacterial infections.
• Fibrosis & bronchiectasis: Scarring narrows airways, causing persistent sputum production and reduced lung capacity.
• Pleural involvement: Effusions or empyema may require drainage.
• Respiratory failure: Extensive parenchymal destruction can lead to hypoxemia, necessitating mechanical ventilation.
• Disseminated (miliary) TB: Hematogenous spread to other organs (brain, liver, bone) carries a high mortality.
• Drug‑induced toxicity: Hepatotoxicity (INH, rifampin, pyrazinamide), optic neuritis (ethambutol), or peripheral neuropathy (INH) can complicate therapy if not monitored.

When to Seek Emergency Care

References

• World Health Organization. Global Tuberculosis Report 2023.
• Centers for Disease Control and Prevention. Tuberculosis Statistics. Updated 2024.
• Mayo Clinic. Tuberculosis – Symptoms and Causes.
• National Institutes of Health, National Institute of Allergy and Infectious Diseases. Tuberculosis (TB) Overview.
• Cleveland Clinic. Tuberculosis (TB).
• American Thoracic Society & CDC. Guidelines for the Treatment of Tuberculosis. 2023.

```